Boehringer Ingelheim Appoints Ms. Alison Barker as Animal Health Director for Taiwan百靈佳殷格翰任命 Alison Barker 女士為台灣動物保健事業處長

台灣, 2025年05月19日 - 12:00

Boehringer Ingelheim is pleased to announce the appointment of Ms. Alison Barker as Animal Health Director, Taiwan, effective May 1, 2025, based in Taipei. She will focus on strengthening the company’s leadership position and long-term development strategy in Taiwan’s animal health market. At the same time, she will become a member of Animal Health TCM Leadership Team, contributing to the implementation of strategic plans and resource alignment across regional markets.

“We are delighted to welcome Ms. Alison Barker to lead our Animal Health business in Taiwan,” said James Chiou, Managing Director, Taiwan. “Her extensive experience in commercial leadership and strategic planning will bring fresh perspectives to our team and support the long-term development of our business in Taiwan.”

Ms. Alison Barker joined Boehringer Ingelheim’s Animal Health business in 2009 and has held multiple leadership roles in Australia and Southeast Asia. She successfully led commercial and marketing initiatives to drive business performance and growth. Most recently she was based in Singapore, leading the commercial execution and business strategy across the Southeast Asia, South Korea, Australia and New Zealand (ASKAN) region.

Ms. Alison Barker holds a veterinary degree from Murdoch University and MBA from Macquarie Graduate School of Management. She brings a wealth of industry knowledge and leadership experience across both developed and emerging markets.

Boehringer Ingelheim is committed to advancing animal health through innovation, with a strong focus on improving the lives of animals and the people who care for them. Ms. Alison Barker’s appointment reflects the company’s ongoing investment in leadership and its commitment to growth and excellence in Taiwan.

Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow.

Boehringer Ingelheim, Taiwan has served in Taiwan since 1975 as a healthy issue solution provider with more than 400 employees and 3 different offices located in north, central and south Taiwan. With core business in Human Pharm and Animal Health, we support patients in the area of the chronic kidney disease, respiratory, oncology, diabetes, cardiovascular, stroke, Parkinson's disease, fibrosis disease and more. We support companion animals and their owners in parasite prevention and the treatment for heart disease and chronic kidney disease, also support livestock farmer in serval disease prevention, such as porcine reproductive and respiratory syndrome, Newcastle Disease and more.